AzurRx BioPharma Announces R&D Update Call on Monday, July 8th at 4:30 PM ET

NEW YORK, July 08, 2019 (GLOBE NEWSWIRE) — AzurRx BioPharma, Inc. (AZRX) (AzurRx or the Company), an organization specializing within the growth of non-systemic, recombinant therapies for gastrointestinal ailments, right this moment introduced that it’ll have a administration R&D replace name.

The R&D replace will function a presentation by Thijs Spoor, CEO; Maged Shenouda, CFO: and Dr. James Pennington, CMO.  The administration crew can be accessible to reply questions.

The Company, together with its Investor Relations agency, LifeSci Advisors, will host the R&D replace name on Monday, July 8th at four:30 p.m. ET.  Investors can be a part of the decision utilizing the next numbers and webcast hyperlink:

About MS1819-SD

MS1819-SD, provided as an oral non-systemic biologic capsule, is a recombinant enzyme that’s derived from the Yarrowia lipolytica lipase, and in contrast to the PERTs-based customary of care, doesn’t include any animal merchandise.

In a Phase II trial of MS1819-SD in sufferers with CP, MS1819-SD confirmed a positive security profile with good tolerability. Additionally, a statistically vital (p=zero.002) enchancment within the coefficient of fats absorption of 21.eight% was noticed the best studied dose (per protocol).

The Company can also be at present conducting the OPTION Study, the Company’s Phase II multi-center examine to research the protection, tolerability and efficacy of MS1819-SD in a head-to-head comparability in opposition to the present PERTs customary of look after EPI in CF sufferers.  The Company just lately introduced the completion of affected person enrollment within the OPTION Study, with top-line outcomes anticipated late Summer 2019.

About Exocrine Pancreatic Insufficiency:

EPI is a situation characterised by deficiency of the exocrine pancreatic enzymes, ensuing within the lack of ability to digest meals correctly, or maldigestion. The deficiency on this enzyme may be liable for greasy diarrhea, fecal urge and weight reduction.

There are roughly 90,000 sufferers within the U.S. with EPI brought on by power pancreatitis in keeping with the National Pancreas Foundation and greater than 30,000 sufferers with EPI brought on by cystic fibrosis in keeping with the Cystic Fibrosis Foundation. Patients are at present handled with porcine pancreatic enzyme alternative tablets.

AzurRx BioPharma, Inc.

AzurRx BioPharma, Inc. (AZRX) is engaged within the analysis and growth of non-systemic biologics for the remedy of sufferers with gastrointestinal problems. MS1819-SD recombinant lipase for EPI is the Company’s lead growth program, and extra early stage analysis is being performed for the prevention of hospital-acquired infections. The Company is headquartered in Brooklyn, NY, with scientific operations based mostly in Langlade, France. Additional info on the Company may be discovered at

Forward-Looking Statements
This press launch could include sure statements regarding future outcomes that are forward-looking statements. These statements aren’t historic info, however as an alternative characterize solely the Company’s perception relating to future occasions, a lot of which, by their nature, are inherently unsure and out of doors of the Company’s management. It is feasible that the Company’s precise outcomes and monetary situation could differ, presumably materially, from the anticipated outcomes and monetary situation indicated in these forward-looking statements. Additional info in regards to the Company and its enterprise, together with a dialogue of things that might materially have an effect on the Company’s monetary outcomes, together with these associated to the medical growth of MS1819-SD and last outcomes of the Phase II OPTION Study, are contained within the Company’s Annual Report on Form 10-Ok for the 12 months ended December 31, 2018 beneath the heading “Risk Factors,” in addition to the Company’s subsequent filings with the Securities and Exchange Commission. All forward-looking statements included on this press launch are made solely as of the date of this press launch, and we don’t undertake any obligation to publicly replace or right any forward-looking statements to replicate occasions or circumstances that subsequently happen or of which we hereafter turn out to be conscious.

For extra info:
AzurRx BioPharma, Inc.
760 Parkside Avenue
Suite 304
Brooklyn, NY 11226
Phone: (646)-699-7855

Investor Relations contact: 
LifeSci Advisors, LLC. 
Hans Vitzthum, Managing Director 
250 West 55th Street – Suite 16B 
New York, NY 10019 
Phone: 617-535-7743

Source hyperlink Weight Loss Without Pills

How do you feel about this post?

Add Comment